Gastroesophageal (GE) Junction Carcinomas – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000
Buy Report

Published: June 05, 2024 Report Code: GDGMDHC23031IDB-L5

Select Item

Empower your strategies with our Gastroesophageal (GE) Junction Carcinomas – Drugs In Development, 2024 report and make more profitable business decisions.

Gastroesophageal (GE) junction carcinomas are malignancies occurring at the point where the esophagus meets the stomach. Typically classified as adenocarcinomas or squamous cell carcinomas, adenocarcinomas are more prevalent. Risk factors include chronic gastroesophageal reflux disease (GERD), obesity, and smoking. Symptoms often manifest in advanced stages, including difficulty swallowing, weight loss, and abdominal pain. Diagnosis involves endoscopic procedures and imaging studies. Treatment may include surgery, chemotherapy, and radiation therapy. Prognosis varies, with early detection improving outcomes. Despite advancements, GE junction carcinomas pose significant challenges, emphasizing the importance of preventive measures and ongoing research for effective management.

The Gastroesophageal (GE) Junction Carcinomas drugs in development market research report provide comprehensive information on the therapeutics under development for Gastroesophageal (GE) Junction Carcinomas, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastroesophageal (GE) Junction Carcinomas and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Gastroesophageal (GE) Junction Carcinomas
Key Targets
· Receptor Tyrosine Protein Kinase ERBB 2; Claudin 18; Programmed Cell Death Protein 1; Tubulin ; Programmed Cell Death 1 Ligand 1; Cytotoxic T Lymphocyte Protein 4; Hepatocyte Growth Factor Receptor; Lymphocyte Activation Gene 3 Protein; Fibroblast Growth Factor Receptor 2; and Vascular Endothelial Growth Factor Receptor 2
Key Mechanisms of Action
· Programmed Cell Death Protein 1 Antagonist; Tubulin Inhibitor; Programmed Cell Death 1 Ligand 1 Inhibitor; Receptor Tyrosine Protein Kinase ERBB 2 Antagonist; Claudin 18 Inhibitor; Lymphocyte Activation Gene 3 Protein Inhibitor; Vascular Endothelial Growth Factor Receptor 2 Inhibitor; Vascular Endothelial Growth Factor Receptor 1 Inhibitor; Vascular Endothelial Growth Factor Receptor Inhibitor; and Proto Oncogene Tyrosine Protein Kinase Receptor Ret Inhibitor
Key Routes of Administration
· Intravenous; Oral; Intravenous Drip; Parenteral; Subcutaneous; Intraperitoneal; Intratumor; Intramuscular; Intravesical; and Intralesional
Key Molecule Types
· Monoclonal Antibody; Small Molecule; Monoclonal Antibody Conjugated; Gene-Modified Cell Therapy; Fusion Protein; Oncolytic Virus; Synthetic Peptide; Recombinant Vector Vaccine; Vaccine; and DNA Vaccine
Major Companies
· Bristol-Myers Squibb Co; BeiGene Ltd; AstraZeneca Plc; MacroGenics Inc; Jiangsu Hengrui Medicine Co Ltd; F. Hoffmann-La Roche Ltd; Alphamab Oncology; Boehringer Ingelheim International GmbH; CSPC Pharmaceutical Group Ltd; and CytomX Therapeutics Inc

Scope

  • Therapeutics in Development: Covering 150 molecules, with 149 developed by companies and the rest by universities/institutes.

  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.

  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.

  • Development History: Access the complete research and development history.

  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Gastroesophageal (GE) Junction Carcinomas therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.

  • Pipeline Exploration: Explore the detailed Gastroesophageal (GE) Junction Carcinomas pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.

  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Gastroesophageal (GE) Junction Carcinomas treatments for adaptable decision-making.

  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

Abbisko Therapeutics Co Ltd
ABL Bio Inc
Adaptimmune Therapeutics Plc
Adlai Nortye Biopharma Co Ltd
Affibody AB
Alligator Bioscience AB
Allorion Therapeutics Inc
Alphamab Oncology
Amgen Inc
Antengene Corp Ltd
Arbele Ltd
Arcus Biosciences Inc
Aslan Pharmaceuticals Ltd
Astellas Pharma Inc
AstraZeneca Plc
Baiya Phytopharm Co Ltd
Basilea Pharmaceutica Ltd
Bavarian Nordic AS
Bayer AG
BeiGene Ltd
Bio-Thera Solutions Ltd
Biotheus Inc
Bliss Biopharmaceutical (Hangzhou) Co Ltd
Boehringer Ingelheim International GmbH
Bold Therapeutics Inc
Bolt Biotherapeutics Inc
Bristol-Myers Squibb Co
CARsgen Therapeutics Ltd
Centrymed Pharmaceutical Inc
Chongqing Precision Biotech Co Ltd
Chugai Pharmaceutical Co Ltd
CSPC Pharmaceutical Group Ltd
CTx Operations Inc
Cue Biopharma Inc
CytomX Therapeutics Inc
D3 Bio Inc
Delta-Fly Pharma Inc
Elevar Therapeutics Inc
Elevation Oncology Inc
Elucida Oncology Inc
Etern BioPharma Co Ltd
Eucure (Beijing) Biopharma Co Ltd
Exelixis Inc
F. Hoffmann-La Roche Ltd
Fog Pharmaceuticals Inc
Genentech USA Inc
Genor BioPharma Co Ltd
GI Innovation Co Ltd
Guangzhou Yinming Biomedical Technology Co Ltd
I-Mab
Idience Co Ltd
Iksuda Therapeutics Ltd
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
ImmuneSensor Therapeutics Inc
ImmunityBio Inc
Immunome Inc
Incyte Corp
Innate Pharma SA
Innovative Cellular Therapeutics Co Ltd
Innovent Biologics Inc
Jazz Pharmaceuticals Plc
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
JSR Life Sciences LLC
LaNova Medicines Ltd
Lepu Biopharma Co Ltd
LianBio
Lisata Therapeutics Inc
Luye Pharma Group Ltd
Lyvgen Biopharma Ltd
MacroGenics Inc
Merck KGaA
Mirati Therapeutics Inc
National Cancer Institute US
NextCure Inc
NextPoint Therapeutics Inc
Nouscom AG
Oncomatryx Biopharma SL
Ono Pharmaceutical Co Ltd
Otsuka Pharmaceutical Co Ltd
Palleon Pharmaceuticals Inc
POINT Biopharma Global Inc
Precirix NV
Protheragen Inc
Purple Biotech Ltd
Qilu Pharmaceutical Co Ltd
Qilu Puget Sound Biotherapeutics Corp
Qurient Co Ltd
RemeGen Co Ltd
Repare Therapeutics Inc
Replimune Ltd
Revolution Medicines Inc
Seagen Inc
Shanghai Haihe Biopharma Co Ltd
Shanghai Henlius Biotech Inc
Shanghai JMT-Bio Technology Co Ltd
Shanghai LiteDD Co Ltd
Shanghai Miracogen Inc
Shijiazhuang Yiling Pharmaceutical Co Ltd
Sosei Group Corp
Starpharma Holdings Ltd
Taiho Pharmaceutical Co Ltd
Tavotek Biotherapeutics
TCRx Therapeutics Co Ltd
Teclison Ltd
Tempest Therapeutics Inc
Toray Industries Inc
Transcenta Holding Ltd
Treadwell Therapeutics Inc
Triumvira Immunologics Inc
Turnstone Biologics Inc
United BioPharma Inc
Volastra Therapeutics Inc
Zai Lab Ltd
Zhejiang Doer Biologics Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overview

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024

Figures

List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Gastroesophageal (GE) Junction Carcinomas reports
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
IgA Nephropathy (Berger’s Disease): Market View, Current and Future Competitive…
$3,495 | June 2026
Pharmaceuticals
New
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Gastroesophageal (GE) Junction Carcinomas – Drugs In Development, 2024 in real time.

  • Access a live Gastroesophageal (GE) Junction Carcinomas – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more